Alk-Abello As B Shs New (AKBLF) Q1 2025 Earnings Call

Investor webinar replay

Replay transcript excerpt

Hello everyone and welcome to this presentation of ALK's Q1 results and full year outlook for 2025. Thank you all for joining us. Let's turn to slide number two with an introduction to the agenda and the speakers. My name is Per Plotnikoff, I am Head of Investor Relations and with me today are CEO Peter Halling and CFO Klaus Steensens earlier. We will first be sharing a few highlights from the quarter, followed by a closer look at the markets, product trends and financials. And we will then provide an update on recent progress on our paediatric agenda and on the NEFI partnership before we move to the full year outlook. As usual, We will end the presentation with a Q&A session. And to get started, I'll hand over to Peter and slide number three for the highlights. Please go ahead, Peter. Thank you, Per, and thank you all for joining today's call. As expected, Q1 results were solid. Revenue grew by 12% to 1.5 billion Danish kroner. Moreover, all sales regions had double-digit growth, and we were pleased to see sales in North America bounce back with 14% growth, as we started to see results from initiatives to get this region back on track. Across regions, tablets stood out as the main contributor to growth. Global tablet sales increased by 22%, and growth was predominantly driven by higher volumes and shipments to our partner, Torii, in Japan. We only had a minor effect from pricing adjustments compared to last year, where improved pricing and rebate adjustments delivered half the growth in our main region, Europe. Within the tablet range, the Hausdorfs MyTablet AcarisX performed very well across markets in Europe and North America. The tablet's new pediatric indication contributed to growth and the initial market response to the launch has been very encouraging. We are...